Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want Congress to take a deeper look at how Biogen’s controversial and pricey new Alzheimer’s drug, Aduhelm, will affect the Medicare program, they wrote in a letter Wednesday.

The bipartisan duo is pressing the Senate Finance Committee to take on “the vexing new questions and challenges that approval raises for the Medicare program and other health programs” the panel oversees, they wrote.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment